Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer

BACKGROUND: To assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer (DTC) treated with sorafenib. FINDINGS: Visual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses were conducted in 63 positron emission tomography (PET) studies performed in patients on sorafenib (group 1, n = 20), in a control group (group 2, n = 28) and in patients on sunitinib or vandetanib (group 3, n = 15). Moderate or high and diffuse bowel uptake (grade 4 or 5) was observed in 90% of the PET scans of group 1 versus none in group 2. Only 20% of PET scans in group 3 were scored grade 4. SUVmax values were significantly higher for all colic segments in group 1 than in group 2 (P < 0.0001) or 3 (P < 0.0004). This uptake pattern appeared rapidly (one month) and disappeared after sorafenib withdrawal. CONCLUSIONS: FDG uptake is increased in the colon of DTC patients treated by sorafenib

Etude PHAD (valeur prédictive des cycles d'ACTH et de cortisol plasmatiques pour l'ajustement du traitement substitutif de l'insuffisant surrénalien)

CAEN-BU Médecine pharmacie (141182102) / SudocSudocFranceF

Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer

International audienc

Postablation 131I scintigraphy with neck and thorax SPECT–CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer

International audienc

Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency

International audienc

The cortisol AUC expressed as mean ± 2 SD (ng/mL/time period) and range values in normal healthy subjects and AI patients.

<p>All statistics are expressed in comparison with control group:</p><p>¹p<0.05,</p><p>²p<0.001.</p><p>AUC: area under curve. AI: adrenal insufficient patients. HC: hydrocortisone.</p><p>The cortisol AUC expressed as mean ± 2 SD (ng/mL/time period) and range values in normal healthy subjects and AI patients.</p

ROC curve analysis of the predictive value of single-point 10 am plasma cortisol for adequate or over-replacement as determined by the comparison of pooled AI patients’ cortisol AUC_8–19h to pooled healthy subjects’ cortisol AUC_8–19h.

<p>ROC curve analysis of the predictive value of single-point 10 am plasma cortisol for adequate or over-replacement as determined by the comparison of pooled AI patients’ cortisol AUC_8–19h to pooled healthy subjects’ cortisol AUC_8–19h.</p

Quality of HC replacement dose adjustment in AI patients who underwent three different HC regimens (6, 10 and 14 mg/ m2/d).

<p>AI: adrenal insufficient. HC: hydrocortisone.</p><p>Quality of HC replacement dose adjustment in AI patients who underwent three different HC regimens (6, 10 and 14 mg/ m2/d).</p

Clinical characteristics of the AI patients.

<p>AI, adrenal insufficiency; APS, autoimmune polyglandular syndrome; HC, hydrocortisone.</p><p>Clinical characteristics of the AI patients.</p